Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | PPM1B | O75688 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4316809 | 0.76 | SMN1; SMN2 (1.00) | SMN1; SMN2HRH4HTR3AHRH3GAA | |
| SCHEMBL22096056 | 0.76 | SMN1; SMN2 (1.00) | SMN1; SMN2HRH4HTR3AHRH3GAA | |
| SCHEMBL12228287 | 0.76 | SMN1; SMN2 (1.00) | SMN1; SMN2HRH4HTR3AHRH3GAA | |
| SCHEMBL4316806 | 0.76 | SMN1; SMN2 (1.00) | SMN1; SMN2HRH4HTR3AHRH3GAA | |
| SCHEMBL26786348 | 0.68 | SMN1; SMN2 (0.67) | SMN1; SMN2HRH4HTR3AHRH3GAA | |
| SCHEMBL23928002 | 0.66 | SMN1; SMN2 (0.57) | SMN1; SMN2HRH4HTR3AHRH3GAA | |
| SCHEMBL8711763 | 0.64 | HRH3 (0.56) | SMN1; SMN2HRH4HTR3AHRH3GAA | |
| SCHEMBL18325628 | 0.60 | HRH4 (1.00) | HRH4HTR3AHRH3 | |
| SCHEMBL186672 | 0.60 | SMN1; SMN2 (0.44) | SMN1; SMN2HRH4HTR3AHRH3GAA | |
| SCHEMBL20827763 | 0.60 | MPG (0.44) | SMN1; SMN2HRH4HTR3AHRH3PPM1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10683300-B2 | Polymorphic forms of Cyclo (-His-Pro) | NOVMETAPHARMA CO., LTD. (KR) | 2020-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10683300-B2 | Polymorphic forms of Cyclo (-His-Pro) | CACYBP, CRHBP, HLA-DRB1 | SMN1; SMN2 4838/4885HRH4 868/4885HTR3A 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.